Investment Securities (Tables)

6 Months Ended

Jan. 31, 2020

Notes to Financial Statements

Marketable Securities

As of January 31, 2019

66,667 Common Shares of Entest Group, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended January  31 2020		Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	1,133	$	480	$	(946)	$	(652)

29,076,665 Common Shares of Regen Biopharma, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended January 31, 2020		Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	17,446	$	2,907	$	(20,353)	$	(14,538)

290,766 Series A Preferred Shares of Regen Biopharma,  Inc.
	Basis	Fair Value		Change in Fair Value for the Quarter ended January 31 2020		Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	29,076	9,595	$	1,454	$	(19,480	)

4,411 Common Shares of Zander Therapeutics, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended January 31 2020			Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	254	$	0	$	(71	)	$	(254	)

5,000 Series M Preferred Shares of Zander Therapeutics, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended January 31, 2020			Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	289	$	0	$	(80	)	$	(289	)

8,333 Series B Preferred Shares of Entest Group, Inc.
	Basis		Fair Value		Change in Fair Value for the Quarter ended January 31 2020		Change in Fair Value for the period from Inception (2/7/1019) to 1/31/2020
$	0	$	0	$	0	$	0